Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, reported financial results for the three and six-months ended June 30, 2010. Related posts Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast (0) Medical Health Insurance [...]

Continue reading " Spectrum Pharmaceuticals Announces Second Quarter 2010 Corporate Update "

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, reported its financial results for the quarter ended September 30, 2009 and provided an update on the Company’s clinical programs. Related posts Men’s Health Month: Recognize Your [...]

Continue reading " ZIOPHARM Reports Third Quarter Financial Results and Updated Clinical Progress "

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, reported its financial results for the quarter ended June 30, 2009 and provided an update on the Company’s clinical programs following the Company’s presentations at the 2009 [...]

Continue reading " ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical Programs "

Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), announced that BiovaxID, Biovest’s personalized anti-cancer vaccine targeting B-cell blood cancers, will be featured in an oral presentation during the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31st, 2009 in Orlando, Florida. Stephen [...]

Continue reading " Personalized Anti-Cancer Vaccine Pivotal Phase III Results to be Presented at ASCO Plenary Session "

Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. Related posts Spectrum [...]

Continue reading " Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care "

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced the appointment of A. Collier Smyth, M.D., former senior vice president of medical strategy – oncology at Bristol-Myers Squibb Company (BMS), to its Board of Directors. Related posts Spectrum Pharmaceuticals Announces Second Quarter 2010 Corporate Update (0) ZIOPHARM Reports Third Quarter Financial Results and Updated Clinical [...]

Continue reading " EpiCept Appoints Recognized Oncology Expert and Pharmaceutical Industry Leader "

AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and [...]

Continue reading " Breakthrough Preclinical Model for Human Cancer May Dramatically Improve Development of Effective Oncology Drugs "